117 related articles for article (PubMed ID: 38336557)
41. Independent dosimetric assessment of the model EP917 episcleral brachytherapy plaque.
Aryal P; Molloy JA; Rivard MJ
Med Phys; 2014 Sep; 41(9):092102. PubMed ID: 25186402
[TBL] [Abstract][Full Text] [Related]
42. Generation and comparison of 3D dosimetric reference datasets for COMS eye plaque brachytherapy using model-based dose calculations.
Fletcher EM; Ballester F; Beaulieu L; Morrison H; Poher A; Rivard MJ; Sloboda RS; Vijande J; Thomson RM
Med Phys; 2024 Jan; 51(1):694-706. PubMed ID: 37665982
[TBL] [Abstract][Full Text] [Related]
43. Gold nanoparticle-based brachytherapy enhancement in choroidal melanoma using a full Monte Carlo model of the human eye.
Asadi S; Vaez-zadeh M; Masoudi SF; Rahmani F; Knaup C; Meigooni AS
J Appl Clin Med Phys; 2015 Sep; 16(5):344–357. PubMed ID: 26699318
[TBL] [Abstract][Full Text] [Related]
44. COMS eye plaque brachytherapy dosimetry simulations for P103d, I125, and C131s.
Melhus CS; Rivard MJ
Med Phys; 2008 Jul; 35(7Part1):3364-3371. PubMed ID: 28513032
[TBL] [Abstract][Full Text] [Related]
45. Dosimetric benefit of a new ophthalmic radiation plaque.
Marwaha G; Wilkinson A; Bena J; Macklis R; Singh AD
Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1226-30. PubMed ID: 22658440
[TBL] [Abstract][Full Text] [Related]
46. egs_brachy: a versatile and fast Monte Carlo code for brachytherapy.
Chamberland MJ; Taylor RE; Rogers DW; Thomson RM
Phys Med Biol; 2016 Dec; 61(23):8214-8231. PubMed ID: 27804922
[TBL] [Abstract][Full Text] [Related]
47. Experimental measurements and Monte Carlo calculations for (103)Pd dosimetry of the 12 mm COMS eye plaque.
Saidi P; Sadeghi M; Tenreiro C
Phys Med; 2013 May; 29(3):286-94. PubMed ID: 22592132
[TBL] [Abstract][Full Text] [Related]
48. Design and dosimetric considerations of a modified COMS plaque: the reusable "seed-guide" insert.
Astrahan MA; Szechter A; Finger PT
Med Phys; 2005 Aug; 32(8):2706-16. PubMed ID: 16193802
[TBL] [Abstract][Full Text] [Related]
49. A comparison of the shielding effectiveness of silicone oil vitreous substitutes when used with Palladium-103 and Iodine-125 eye plaques.
Yang YM; Chow PE; McCannel TA; Lamb JM
Med Phys; 2019 Feb; 46(2):1006-1011. PubMed ID: 30554429
[TBL] [Abstract][Full Text] [Related]
50. 125I eye plaque dose distribution including penumbra characteristics.
de la Zerda A; Chiu-Tsao ST; Lin J; Boulay LL; Kanna I; Kim JH; Tsao HS
Med Phys; 1996 Mar; 23(3):407-18. PubMed ID: 8815384
[TBL] [Abstract][Full Text] [Related]
51. Update of the CLRP Monte Carlo TG-43 parameter database for high-energy brachytherapy sources.
Safigholi H; Chamberland MJP; Taylor REP; Martinov MP; Rogers DWO; Thomson RM
Med Phys; 2023 Mar; 50(3):1928-1941. PubMed ID: 36542404
[TBL] [Abstract][Full Text] [Related]
52. Measured, calculated, and egs_brachy I-125 dose distributions in a gold plaque for retinoblastoma treatment.
Trauernicht CJ; van Eeden D; du Plessis FCP
Med Phys; 2022 Sep; 49(9):6183-6194. PubMed ID: 35792659
[TBL] [Abstract][Full Text] [Related]
53. 106Ru/106Rh plaque and proton radiotherapy for ocular melanoma: a comparative dosimetric study.
Mourtada F; Koch N; Newhauser W
Radiat Prot Dosimetry; 2005; 116(1-4 Pt 2):454-60. PubMed ID: 16604677
[TBL] [Abstract][Full Text] [Related]
54. COMS eye plaque brachytherapy dosimetric sensitivity to source photon energy and seed design.
Gagne NL; Rivard MJ
Appl Radiat Isot; 2013 Sep; 79():62-6. PubMed ID: 23728350
[TBL] [Abstract][Full Text] [Related]
55. How to design, fabricate, and validate a customized COMS-style eye plaque: Illustrated with a narrow-slotted plaque example.
Deufel CL; Dalvin LA; Qian J; Vaishnav B; Cutsinger JM; Wittich MN; Petersen IA
Brachytherapy; 2021; 20(6):1235-1244. PubMed ID: 34217602
[TBL] [Abstract][Full Text] [Related]
56. Ocular malignancies treated with iodine-125 low dose rate (LDR) brachytherapy at a single high-volume institution: A retrospective review.
Richards Z; Nguyen ML; Kutteh M; Ahmad S; Henson C; Firestone B; Herman TS; Herman TF
Med Dosim; 2022 Autumn; 47(3):273-279. PubMed ID: 35644778
[TBL] [Abstract][Full Text] [Related]
57. Improvement of dose distribution in ocular brachytherapy with
Zabihzadeh M; Rezaee H; Hosseini SM; Feghhi M; Danyaei A; Hoseini-Ghahfarokhi M
J Cancer Res Ther; 2019; 15(3):504-511. PubMed ID: 31169211
[TBL] [Abstract][Full Text] [Related]
58. Episcleral eye plaque dosimetry comparison for the Eye Physics EP917 using Plaque Simulator and Monte Carlo simulation.
Zimmermann LW; Amoush A; Wilkinson DA
J Appl Clin Med Phys; 2015 Nov; 16(6):226-239. PubMed ID: 26699577
[TBL] [Abstract][Full Text] [Related]
59. [Brachytherapy of ocular melanoma: physical and dosimetric aspects of 125I plaques].
Bard JJ
Bull Cancer Radiother; 1995; 82(3):295-305. PubMed ID: 8554879
[TBL] [Abstract][Full Text] [Related]
60. Sci-Sat AM(2): Brachy-03: Monte Carlo dosimetry for I-125 and Pd-103 eye plaque brachytherapy.
Thomson RM; Taylor R; Rogers D
Med Phys; 2008 Jul; 35(7Part3):3416. PubMed ID: 28512876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
